Literature DB >> 27994690

Unusual Uptake of Prostate Specific Tracer 68Ga-PSMA-HBED-CC in a Benign Thyroid Nodule.

Nishikant Avinash Damle1, Madhavi Tripathi1, Partha Sarathi Chakraborty1, Manas Kumar Sahoo1, Chandrasekhar Bal1, Shipra Aggarwal2, Geetanjali Arora1, Praveen Kumar1, Rajeev Kumar1, Ravikant Gupta1.   

Abstract

68Ga-Prostate specific membrane antigen- N,N'-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid- positron emission tomography/computed tomography or 68 Ga- HBED-CC-PSMA PET/CT, popularly known as PSMA PET/CT, is able to detect a small volume of recurrent prostate carcinoma (PC) when there is a prostate specific antigen (PSA) rise on follow-up after prostatectomy or other definitive treatment for PC. The use of PSMA PET/CT in the initial staging in PC is uncertain at this time. Clinical studies are underway to define its exact role in the management of the disease. At the same time it is important to be aware of unexpected sites of uptake of this ligand. We present here the case of a 62-year-old male patient who underwent prostatectomy for adenocarcinoma prostate. He also had a long-standing left solitary thyroid nodule (STN). Four months after surgery, he had a rising trend in serum PSA levels on three occasions, but the absolute value was less than 4 at all times. He underwent a 68Ga-PSMA-HBED-CC PET/CT, but it did not reveal any recurrent/metastatic site of disease. However, there was increased tracer uptake in the left STN. Fine needle aspiration cytology revealed features of atypia of undetermined significance, Bethesda category III. The patient underwent a left hemithyroidectomy and the histopathology showed features of a follicular adenoma.

Entities:  

Keywords:  68Gallium; PET/CT; PSMA; Prostate carcinoma

Year:  2016        PMID: 27994690      PMCID: PMC5135692          DOI: 10.1007/s13139-016-0408-y

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  15 in total

1.  [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.

Authors:  A Afshar-Oromieh; U Haberkorn; M Eder; M Eisenhut; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-04       Impact factor: 9.236

2.  (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Authors:  Emre Demirci; Meltem Ocak; Levent Kabasakal; Clemens Decristoforo; Zübeyir Talat; Metin Halaç; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-23       Impact factor: 9.236

3.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

Review 4.  Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging.

Authors:  Kirsten Bouchelouche; Baris Turkbey; Peter Choyke; Jacek Capala
Journal:  Curr Urol Rep       Date:  2010-05       Impact factor: 3.092

5.  Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT.

Authors:  Partha Sarathi Chakraborty; Madhavi Tripathi; Krishan Kant Agarwal; Rajeev Kumar; Maneesh Kumar Vijay; Chandrasekhar Bal
Journal:  Clin Nucl Med       Date:  2015-02       Impact factor: 7.794

Review 6.  [Ga-68-PSMA PET/CT for prostate cancer].

Authors:  D Hellwig; J Moosbauer; C Eilles
Journal:  Aktuelle Urol       Date:  2014-12-17       Impact factor: 0.658

7.  Thyroid incidentalomas discovered on positron emission tomography CT scanning - Malignancy rate and significance of standardised uptake values.

Authors:  R Brindle; D Mullan; B K Yap; A Gandhi
Journal:  Eur J Surg Oncol       Date:  2014-05-24       Impact factor: 4.424

8.  Prostate-specific membrane antigen expression in normal and malignant human tissues.

Authors:  D A Silver; I Pellicer; W R Fair; W D Heston; C Cordon-Cardo
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

9.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors:  A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-24       Impact factor: 9.236

10.  A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.

Authors:  Martin Schäfer; Ulrike Bauder-Wüst; Karin Leotta; Frederic Zoller; Walter Mier; Uwe Haberkorn; Michael Eisenhut; Matthias Eder
Journal:  EJNMMI Res       Date:  2012-06-06       Impact factor: 3.138

View more
  7 in total

Review 1.  Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.

Authors:  Prasanna Santhanam; Lilja B Solnes; Steven P Rowe
Journal:  Med Oncol       Date:  2017-10-30       Impact factor: 3.064

2.  Anaplastic thyroid carcinoma on 68 Ga-PSMA PET/CT: opening new frontiers.

Authors:  Nishikant Avinash Damle; Chandrasekhar Bal; Tejesh Pratap Singh; Ravikant Gupta; Sreenivasa Reddy; Rajeev Kumar; Madhavi Tripathi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-02       Impact factor: 9.236

3.  A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.

Authors:  Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-04       Impact factor: 9.236

4.  68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients.

Authors:  Paola Caroli; Israel Sandler; Federica Matteucci; Ugo De Giorgi; Licia Uccelli; Monica Celli; Flavia Foca; Domenico Barone; Antonino Romeo; Anna Sarnelli; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-19       Impact factor: 9.236

5.  PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.

Authors:  Andrey Bychkov; Usanee Vutrapongwatana; Supatporn Tepmongkol; Somboon Keelawat
Journal:  Sci Rep       Date:  2017-07-12       Impact factor: 4.379

6.  Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Authors:  Ali Afshar-Oromieh; Tim Holland-Letz; Frederik L Giesel; Clemens Kratochwil; Walter Mier; Sabine Haufe; Nils Debus; Matthias Eder; Michael Eisenhut; Martin Schäfer; Oliver Neels; Markus Hohenfellner; Klaus Kopka; Hans-Ulrich Kauczor; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-12       Impact factor: 9.236

7.  Prostate-specific Membrane Antigen Imaging in Recurrent Medullary Thyroid Cancer: A New Theranostic Tracer in the Offing?

Authors:  Saurabh Arora; Meghana Prabhu; Nishikant Avinash Damle; Chandrasekhar Bal; Praveen Kumar; Harish Nalla; Sreedharan Thankarajan Arun Raj
Journal:  Indian J Nucl Med       Date:  2018 Jul-Sep
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.